Browse our 650+ Publications​

Latest Publications

T-cell receptor diversity in minimal change disease in the NEPTUNE study

Liu S, et al.
August 2022
Authors and Affiliates
Shiying Liu 1,2, William S Bush 1,2,3, Kristy Miskimen 1,2,3, Agustin Gonzalez-Vicente 4, Jessica N Cooke Bailey 1,2, Ioanna Konidari 5, Jacob L McCauley 5, John R Sedor 4, John F O'Toole 4, Dana C Crawford 6,7,8; 1 Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA. 2 Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA. 3 Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA. 4 Glickman Urological and Kidney Disease and Lerner Research Institutes, Cleveland Clinic, Cleveland, OH, USA. 5 John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA. 6 Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA. dana.crawford@case.edu. 7 Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA. dana.crawford@case.edu. 8 Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA. dana.crawford@case.edu.

Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers

Apavaloaei A, et al.
Cell Reports
August 2022
Authors and Affiliates
Anca Apavaloaei 1, Leslie Hesnard 2, Marie-Pierre Hardy 2, Basma Benabdallah 3, Gregory Ehx 2, Catherine Thériault 2, Jean-Philippe Laverdure 2, Chantal Durette 2, Joël Lanoix 2, Mathieu Courcelles 2, Nandita Noronha 1, Kapil Dev Chauhan 4, Sébastien Lemieux 5, Christian Beauséjour 6, Mick Bhatia 7, Pierre Thibault 8, Claude Perreault 9; 1 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; Department of Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada. 2 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada. 3 CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada. 4 Faculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada. 5 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada. 6 CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada; Department of Pharmacology and Physiology, University of Montreal, Montreal, QC H3T 1J4, Canada. 7 Faculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada. 8 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; Department of Chemistry, University of Montreal, Montreal, QC H3T 1J4, Canada. Electronic address: pierre.thibault@umontreal.ca. 9 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; Department of Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada. Electronic address: claude.perreault@umontreal.ca.

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Palmer CD, et al.
Nature Medicine
August 2022
Authors and Affiliates
Christine D Palmer 1, Amy R Rappaport 1, Matthew J Davis 1, Meghan G Hart 1, Ciaran D Scallan 1, Sue-Jean Hong 1, Leonid Gitlin 1, Lauren D Kraemer 1, Sonia Kounlavouth 1, Aaron Yang 1, Lindsey Smith 1, Desiree Schenk 1, Mojca Skoberne 1, Kiara Taquechel 1, Martina Marrali 1, Jason R Jaroslavsky 1, Charmaine N Nganje 1, Elizabeth Maloney 1, Rita Zhou 1, Daniel Navarro-Gomez 1, Adrienne C Greene 1, Gijsbert Grotenbreg 1, Renee Greer 1, Wade Blair 1, Minh Duc Cao 1, Shawn Chan 1, Kyounghwa Bae 1, Alexander I Spira 2, Sameek Roychowdhury 3, David P Carbone 3, Brian S Henick 4, Charles G Drake 4, Benjamin J Solomon 5, Daniel H Ahn 6, Amit Mahipal 7, Steve B Maron 8, Benny Johnson 9, Raphael Rousseau 1, Roman Yelensky 1, Chih-Yi Liao 10, Daniel V T Catenacci 10, Andrew Allen 1, Andrew R Ferguson 1, Karin Jooss 11; 1 Gritstone bio, Inc., Emeryville, CA, USA. 2 Virginia Cancer Specialists, Virginia Cancer Specialists, VA, Fairfax, USA. 3 The Ohio State University Medical Center, Columbus, OH, USA. 4 Columbia University Medical Center, New York, NY, USA. 5 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 6 Mayo Clinic, Phoenix, AZ, USA. 7 Mayo Clinic Cancer Center, Rochester, MN, USA. 8 Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9 The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 10 University of Chicago Comprehensive Cancer Center, Chicago, IL, USA. 11 Gritstone bio, Inc., Emeryville, CA, USA. kjooss@gritstone.com.

The RAG1 Ubiquitin Ligase Domain Stimulates Recombination of TCRβ and TCRα Genes and Influences Development of αβ T Cell Lineages

Burn TN, et al.
Journal of Immunology
August 2022
Authors and Affiliates
Thomas N Burn 1,2, Charline Miot 3, Scott M Gordon 1,4, Erica J Culberson 3, Tamir Diamond 1,5, Portia A Kreiger 3, Katharina E Hayer 6, Anamika Bhattacharyya 7, Jessica M Jones 7, Craig H Bassing 8,3,9, Edward M Behrens 8,2; 1 Penn Institute for Immunology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 2 Division of Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA. 3 Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA. 4 Division of Neonatology, The Children's Hospital of Philadelphia, Philadelphia, PA. 5 Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA. 6 Department of Biomedical and Health Bioinformatics, The Children's Hospital of Philadelphia, Philadelphia, PA. 7 Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC; and. 8 Penn Institute for Immunology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; bassing@chop.edu behrens@chop.edu. 9 Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer

Hoyos V, et al.
August 2022
Authors and Affiliates
Valentina Hoyos 1, Spyridoula Vasileiou 2, Manik Kuvalekar 2, Ayumi Watanabe 2, Ifigeneia Tzannou 2, Yovana Velazquez 2, Matthew French-Kim 2, Wingchi Leung 2, Suhasini Lulla 2, Catherine Robertson 2, Claudette Foreman 3, Tao Wang 3, Shaun Bulsara 3, Natalia Lapteva 2, Bambi Grilley 2, Matthew Ellis 3, Charles Kent Osborne 3, Angela Coscio 3, Julie Nangia 3, Helen E Heslop 2, Cliona M Rooney 2, Juan F Vera 2, Premal Lulla 2, Mothaffar Rimawi 3, Ann M Leen 2; 1 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, 1102 Bates Ave, Feigin Center 17th Floor. Houston, TX 77030, USA. 2 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA. 3 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity

Ruck T, et al.
August 2022
Authors and Affiliates
Tobias Ruck 1,2, Sumanta Barman 2, Andreas Schulte-Mecklenbeck 1, Steffen Pfeuffer 1, Falk Steffen 3, Christopher Nelke 1, Christina B Schroeter 2, Alice Willison 2, Michael Heming 1, Thomas Müntefering 2, Nico Melzer 1, Julia Krämer 1, Maren Lindner 1, Marianne Riepenhausen 1, Catharina C Gross 1, Luisa Klotz 1, Stefan Bittner 3, Paolo A Muraro 4, Tilman Schneider-Hohendorf 1, Nicholas Schwab 1, Gerd Meyer Zu Hörste 1, Norbert Goebels 2, Sven G Meuth 1 2, Heinz Wiendl 1; 1 Department of Neurology with Institute of Translational Neurology, University Hospital Muenster, 48149 Muenster, Germany. 2 Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany. 3 Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. 4 Department of Brain Sciences, Imperial College London, London, UK.

Symptom burden and immune dynamics 6 to 18 months following mild SARS-CoV-2 infection -a case-control study

Fjelltveit EB, et al.
August 2022
Authors and Affiliates
Elisabeth B Fjelltveit 1,2, Bjørn Blomberg 3,4, Kanika Kuwelker 3,5, Fan Zhou 1, Therese B Onyango 1, Karl A Brokstad 1,6, Rebecca Elyanow 7, Ian M Kaplan 7, Camilla Tøndel 3,8,9, Kristin G I Mohn 1,5, Türküler Özgümüş 10, Rebecca J Cox 1,2, Nina Langeland 3,4, Bergen COVID-19 Research Group; 1 Influenza Centre, Department of Clinical Science, University of Bergen; Bergen, Norway. 2 Department of Microbiology, Haukeland University Hospital; Bergen, Norway. 3 Department of Clinical Science, University of Bergen; Bergen, Norway. 4 National Advisory Unit for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital; Bergen, Norway. 5 Department of Medicine, Haukeland University Hospital, Bergen, Norway. 6 Department of Safety, Chemistry and Biomedical Laboratory Sciences, Western Norway University of Applied Sciences, Bergen, Norway. 7 Adaptive Biotechnologies, Seattle, WA, USA. 8 Department of Research and Development, Haukeland University Hospital, Bergen, Norway. 9 Department of Pediatrics, Haukeland University Hospital, Bergen, Norway. 10 Department of Global Public Health and Primary Care, University of Bergen; Bergen, Norway.

Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

Kim SP, et al.
Cancer Immunology Research
August 2022
Authors and Affiliates
Sanghyun P Kim 1, Nolan R Vale 1, Nikolaos Zacharakis 1, Sri Krishna 1, Zhiya Yu 1, Billel Gasmi 2, Jared J Gartner 1, Sivasish Sindiri 1, Parisa Malekzadeh 1, Drew C Deniger 1, Frank J Lowery 1, Maria R Parkhurst 1, Lien T Ngo 1, Satyajit Ray 1, Yong F Li 1, Victoria Hill 1, Maria Florentin 1, Robert V Masi 1, Biman C Paria 1, Noam Levin 1, Alakesh Bera 1, Elizabeth A Hedges 1, Agnes Choi 1, Praveen D Chatani 1, Anup Y Parikh 1, Shoshana Levi 1, Samantha Seitter 1, Yong-Chen Lu 1, Zhili Zheng 1, Todd D Prickett 1, Li Jia 3, Jonathan M Hernandez 4, Chuong D Hoang 5, Paul F Robbins 1, Stephanie L Goff 1, Richard M Sherry 1, James C Yang 1, Steven A Rosenberg 1; 1 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2 Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland. 3 National Institutes of Health Library, Office of Director, National Institutes of Health, Bethesda, Maryland. 4 Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 5 Thoracic Surgery Branch, National Cancer Institute, NIH, CCR and The Clinical Center, Bethesda, Maryland.

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling

Fix SM, et al.
Journal for ImmunoTherapy of Cancer
August 2022
Authors and Affiliates
Samantha M Fix 1, Marie-Andrée Forget 1, Donastas Sakellariou-Thompson 1, Yunfei Wang 1, Tamara M Griffiths 2, Minjung Lee 3, Cara L Haymaker 3, Ana Lucía Dominguez 1, Rafet Basar 4, Christopher Reyes 5, Sanjay Kumar 5, Larissa A Meyer 6, Patrick Hwu #,7, Chantale Bernatchez #,1, Amir A Jazaeri #,6; 1 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2 Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3 Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 4 Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5 Cell Biology R&D, Thermo Fisher Scientific, Carlsbad, California, USA. 6 Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 7 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Patrick.Hwu@moffitt.org. # Contributed equally.
Previous Next